Oriol Mirallas, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses real-world genomic data involving the next-generation sequencing (NGS) of gliomas, allowing clinicians to appropriately treat patients based on disease genotype. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.